Search results for "Polyethylene"

showing 10 items of 809 documents

Current practice of hepatitis C treatment in Southern Italy.

2010

Abstract Background Only a small proportion of subjects referring to hospitals for hepatitis C virus (HCV) positivity receives antiviral therapy. Aim To evaluate the rate of antiviral treatment and the causes for no treatment in HCV-RNA positive subjects seen in hospital settings. Patients and methods A prospective study enrolling over a 6-month period (February–July 2009) all consecutive anti-HCV positive subjects initially referred (naive patients) to 12 liver units in Southern Italy for HCV treatment. Results Out of 608 subjects evaluated, 74 (12.2%) had no detectable HCV-RNA in the serum and thus were excluded. Of the remaining 534 HCV-RNA positive subjects, 357 (66.9%) were not treated…

AdultMalemedicine.medical_specialtyMultivariate analysisHepatitis C virusAlcohol abuseHepacivirusInterferon alpha-2medicine.disease_causeAntiviral AgentsPolyethylene GlycolsTreatment RefusalSex FactorsInternal medicineRibavirinHumansMedicineProspective StudiesProspective cohort studyAgedHepatologybusiness.industryGastroenterologyAntiviral therapyInterferon-alphaAlanine TransaminaseHepatitis CHepatitis C AntibodiesMiddle Agedmedicine.diseaseHepatitis CRecombinant ProteinsAlcoholismTreatment OutcomeItalyCurrent practiceImmunologyHCVHcv treatmentEducational StatusRNA ViralFemalebusiness
researchProduct

Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.

2006

: Background/Aim: Liver steatosis (LS) has been variably associated with chronic hepatitis C (CHC) but whether it affects sustained virological response to antiviral treatment and by what mechanisms is a question still under debate, at least for some genotypes. The aim of this work was to assess the frequency of LS, its relationship with host and viral factors and to what extent it can influence the response to antiviral combination therapy with pegylated interferon (INF)+ribavirin in a group of patients with CHC from a single center. Patients: One hundred and twelve patients with histologically proven CHC were treated with Peg INF-α 2a 180 μg a week subcutaneously for 48 weeks plus ribavir…

AdultMalemedicine.medical_specialtyPathologyAgingCombination therapyGenotypeHepatitis C virusantiviral treatmentHepacivirusInterferon alpha-2Single Centermedicine.disease_causeGastroenterologyAntiviral AgentsSeverity of Illness IndexBody Mass IndexPolyethylene Glycolsliver steatosischemistry.chemical_compoundPegylated interferonInternal medicineGenotypeRibavirinmedicinechronic hepatitis CHumansAspartate AminotransferasesHepatologybusiness.industryRibavirinInterferon-alphaAlanine Transaminasegamma-GlutamyltransferaseHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsFatty LiverTreatment OutcomechemistryLiverDrug Therapy CombinationFemaleSteatosisbusinessBody mass indexmedicine.drugLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.

2021

Summary Background There is no evidence that phlebotomy alone is sufficient to steadily maintain haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to compare the efficacy and safety of ropeginterferon alfa-2b on top of the standard phlebotomy regimen with phlebotomy alone. Methods In 2017, we launched the Low-PV study, a multicentre, open-label, two-arm, parallel-group, investigator-initiated, phase 2 randomised trial with a group-sequential adaptive design. The study involved 21 haematological centres across Italy. Participants were recruited in a consecutive order. Participants enrolled in the study were patients, aged 18–60 years, with a diagnosis…

AdultMalemedicine.medical_specialtyPolycythaemiaNeutropeniaAdolescentPolicithemia veraInterferon alpha-2Polymorphism Single Nucleotidelaw.inventionPolyethylene Glycols03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled trialPhlebotomylawBone MarrowInternal medicinemedicineClinical endpointData monitoring committeeHumansPolycythemia Verabusiness.industryStandard treatmentInterferon-alphaHematologyPhlebotomyJanus Kinase 2Middle AgedInterim analysismedicine.diseaseRecombinant ProteinsRegimenTreatment Outcome030220 oncology & carcinogenesisQuality of LifeFemalebusiness030215 immunologyThe Lancet. Haematology
researchProduct

Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks

2011

Guidelines recommend that patients with chronic hepatitis C virus (HCV) infection be treated with pegylated interferon and ribavirin for 24, 48, or 72 weeks, based on their virologic response to treatment. We investigated the effects of treating patients for individualized durations.We treated 398 treatment-naïve patients who had HCV genotype 1 infections with pegylated interferon alfa-2b and ribavirin for 24, 30, 36, 42, 48, 60, or 72 weeks (mean of 39 weeks, termed individualized therapy); the duration of therapy was determined based on baseline viral load and the time point at which HCV RNA levels became undetectable (measured at weeks 4, 6, 8, 12, 24, and 30). Results were compared with…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentGenotypeTranscription-mediated amplificationHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyVirusPolyethylene GlycolsYoung AdultLiver diseasechemistry.chemical_compoundPegylated interferonGermanyInternal medicineRibavirinHumansMedicinePrecision MedicineAgedDose-Response Relationship DrugHepatologybusiness.industryStandard treatmentRibavirinGastroenterologyInterferon-alphavirus diseasesHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant Proteinsdigestive system diseasesClinical trialTreatment OutcomechemistryImmunologyRNA ViralDrug Therapy CombinationFemalebusinessViral loadmedicine.drugGastroenterology
researchProduct

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study.

2006

Early treatment of acute hepatitis C with interferon alpha-2b for 24 weeks prevents chronic infection in almost all patients. Because pegylated interferons have replaced conventional interferon in the therapy of chronic hepatitis C, the aim of this study was to analyze the efficacy of an early treatment of acute hepatitis C with peginterferon alpha-2b. Between February 2001 and February 2004, 89 individuals with acute HCV infection were recruited at 53 different centers in Germany. Patients received 1.5 microg/kg peginterferon alpha-2b for 24 weeks; treatment was initiated after a median of 76 days after infection (range 14-150). End-of-treatment response and sustained virological response …

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentPegylated interferon alpha-2b610 MedizinInterferon alpha-2GastroenterologyPolyethylene GlycolsInterferonInternal medicineMedicineHumansAgedHepatologybusiness.industryInterferon-alphaMiddle AgedHepatitis CRecombinant ProteinsClinical trialChronic infectionCytokineImmunologyAcute DiseasePopulation studyPatient ComplianceFemaleViral diseaseAcute hepatitis Cbusinessmedicine.drugHepatology (Baltimore, Md.)
researchProduct

Predicting Early and Sustained Virological Responses in Prior Nonresponders to Pegylated Interferon alpha-2b Plus Ribavirin Retreated With Peginterfe…

2013

GOALS: To evaluate the predictive value of complete early virological response (cEVR) on sustained virological response (SVR) following retreatment with peginterferon alpha-2a (40 kDa) plus ribavirin in previous nonresponders to peginterferon alpha-2b (12 kDa). BACKGROUND: In the randomized multinational retreatment with Pegasys in patients not responding to PegIntron therapy study, a 72-week regimen of peginterferon alpha-2a (40 kDa) plus ribavirin improved SVR rates over a standard 48-week regimen in previous nonresponders to peginterferon alpha-2b (12 kDa). cEVR, defined as hepatitis C virus RNA <50 IU/mL at treatment week 12, was an important predictor of SVR. STUDY: We conducted an exp…

AdultMalemedicine.medical_specialtyTime FactorsInterferon alpha-2Antiviral therapyAntiviral AgentsGastroenterologyPolyethylene Glycolslaw.inventionchemistry.chemical_compoundPharmacotherapyRandomized controlled trialnonresponderPredictive Value of TestslawInternal medicineRibavirinchronic hepatitis CHumansMedicinepeginterferonAdverse effectRandomized Controlled Trials as Topicbusiness.industryRibavirinGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasepeginterferon; chronic hepatitis C; nonresponder; retreatment; sustained virological responseRecombinant Proteinsdigestive system diseasesRegimenTreatment OutcomechemistryPredictive value of testsRelative riskRetreatmentDrug Therapy CombinationFemalesustained virological responsebusinessJournal of Clinical Gastroenterology
researchProduct

Long-term results of the use of silicone sheets after diskectomy in the temporomandibular joint: clinical, radiographic and histopathologic findings

1999

The aim of the present study was to evaluate the long-term results of a group of patients who had the disk of the temporomandibular joint (TMJ) removed and permanently replaced by a silicone sheet. The study group comprised 48 patients, treated in the period from 1983 to 1993. In eight patients, the implants had to be removed after an average interval of 5.6 years and they were submitted for histopathological examination. Twenty-five of the 40 patients with silastic implants in place, and five of the 8 patients who had their implants removed, were available for long-term follow-up (mean interval of 7.0 years, SD 2.8 years). Clinical function was rated according to the Helkimo Dysfunction In…

AdultMalemedicine.medical_specialtyTime FactorsJoint ProsthesisRadiographySiliconesPalpationCondylechemistry.chemical_compoundSiliconeRadiography PanoramicTemporomandibular Joint DiscmedicineHumansDimethylpolysiloxanesDiskectomyDevice RemovalAgedChi-Square Distributionmedicine.diagnostic_testPolyethylene Terephthalatesbusiness.industryMiddle AgedSilasticProsthesis FailureTemporomandibular jointSurgerymedicine.anatomical_structureOtorhinolaryngologychemistryFemaleSurgeryHistopathologyOral SurgerybusinessFollow-Up StudiesInternational Journal of Oral and Maxillofacial Surgery
researchProduct

Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents

2013

Abstract Background In chronic genotype 1 hepatitis C, telaprevir or boceprevir plus peginterferon and ribavirin have become the new standard of care. Aim of this study was to identify factors contributing to the decision whether to defer or treat with the current triple regimens. Methods Prospective assessment of eight parameters on 0-4-point scales by the attending physician at a German tertiary referral centre between 1st September 2011 and 31st December 2012. Results 307 patients were evaluated at least once by one of the 11 hepatologists involved; 267 patients were considered, but only 163 were recommended to receive triple therapy. Multivariate regression analysis revealed that a high…

AdultMalemedicine.medical_specialtyTime FactorsProlineDecision MakingHepacivirusPharmacologyAntiviral AgentsSeverity of Illness IndexPolyethylene GlycolsTelaprevirCohort Studieschemistry.chemical_compoundFibrosisBoceprevirInternal medicineDrug DiscoveryRibavirinGenotypemedicineHumansDecompensationProspective StudiesWatchful WaitingAgedDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaPatient PreferenceHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseLogistic ModelschemistryTolerabilityMultivariate AnalysisDisease ProgressionDrug Therapy CombinationFemalebusinessOligopeptidesmedicine.drugDigestive and Liver Disease
researchProduct

Forty-slice MDCT enteroclysis: evaluation after oral administration of isotonic solution in Crohn's disease.

2007

Objective. The aim of this study was to evaluate the accuracy of multidetector computed tomography (MDCT) enteroclysis after oral hyperhydration with isotonic solution in detecting bowel wall alterations in patients with Crohn’s disease. Materials and methods. Twenty-eight patients with a diagnosis of Crohn’s disease established by ileocolonoscopy and histology were enrolled in the study; 15 patients with negative ileocolonoscopy served as controls. In all cases, MDCT enteroclysis was performed after oral administration of 2,000 ml of isotonic solution and intravenous administration of N-butylscopolamine. Axial, isotropic multiplanar and volume-rendered reconstructions were used to evaluate…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentAdministration OralContrast MediaIntestino tenueSensitivity and SpecificityPolyethylene GlycolsCrohn DiseaseOral administrationPatologie gastrointestinaliIntestine SmallMedicineIntubationHumansRadiology Nuclear Medicine and imagingNeuroradiologyTC multidetettoreCrohn's diseasemedicine.diagnostic_testbusiness.industryCatharticsMultidetector CTUltrasoundInterventional radiologyGeneral MedicineEnemamedicine.diseaseGastrointestinal diseaseSmall boweldigestive system diseasesSpiral computed tomographyIopamidolFemaleRadiologyIsotonic SolutionsbusinessTomography X-Ray ComputedLa Radiologia medica
researchProduct

Crohn's disease: A comparative prospective study of transabdominal ultrasonography, small intestine contrast ultrasonography, and small bowel enema

2005

Background: Small intestine contrast ultrasonography (SICUS), when performed after distention of the small bowel lumen with an iso-osmolar polyethylene glycol electrolyte-balanced solution, shows high sensitivity (100%) and specificity (97%) in detecting small bowel abnormalities in patients who have not received a diagnosis but in whom there is a suspicion of intestinal diseases. The diagnostic yield of SICUS remains to be established in detecting small bowel lesions in patients with proven Crohn's disease (CD) in comparison with transabdominal ultrasonography (TUS), and in relationship to the experience of the operator, using small bowel enema (SBE) as the “gold standard.” Aim: The aim of…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentContrast MediaSmall bowel enemaLumen (anatomy)EnemaSensitivity and SpecificityGastroenterologyPolyethylene GlycolsDiagnosis DifferentialJejunumSettore MED/12Professional CompetenceCrohn DiseaseInternal medicineAbdomenIntestine SmallmedicineHumansImmunology and AllergyProspective cohort studyUltrasonographyCrohn's diseaseSicusbiologybusiness.industryGastroenterologyEnemaMiddle AgedSmall bowelmedicine.diseasebiology.organism_classificationSmall intestineCrohn's diseaseStenosismedicine.anatomical_structureSolventsFemalebusinessDilatation Pathologic
researchProduct